A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients - FINE Trial.
Multiple sclerosis
fingolimod
patient satisfaction
quality of life
Journal
Noro psikiyatri arsivi
ISSN: 1300-0667
Titre abrégé: Noro Psikiyatr Ars
Pays: Turkey
ID NLM: 9426194
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
03
02
2017
accepted:
11
05
2017
entrez:
7
1
2020
pubmed:
22
6
2017
medline:
22
6
2017
Statut:
epublish
Résumé
To assess satisfaction and quality of life in patients with relapsing-remitting multiple sclerosis (RRMS) who were receiving fingolimod (0.5 mg/day) for 12 months as a second-line treatment after switching from injectable agents. Patients aged 18-65 years with RRMS who fulfilled the eligibility criteria were enrolled from 16 centers throughout Turkey. Treatment Satisfaction Questionnaire for Medication and 36-item Short-Form Health Survey were completed at baseline and four visits to assess patient satisfaction and quality of life. Forty-two patients (62% male; mean age: 35.7±9.4 years) were eligible for inclusion. Patient satisfaction scores at the end of the study (44.7±9.9) were significantly higher than those at baseline [32.0±9.9; (p<0.001)]. The only significant increase in the quality of life survey was in the emotional aspect (p=0.019). There were 124 adverse events and none of the five serious adverse events noted was considered drug-related. Large-scale comparative studies performed with disease specific quality of life instruments will allow more information on this issue.
Identifiants
pubmed: 31903032
doi: 10.5152/npa.2017.20515
pii: archneuro-56-253
pmc: PMC6927087
doi:
Types de publication
Journal Article
Langues
eng
Pagination
253-257Informations de copyright
Copyright: © 2019 Turkish Neuropsychiatric Society.
Déclaration de conflit d'intérêts
Conflict of Interest: No conflict of interest was declared by the authors.
Références
Drug Healthc Patient Saf. 2015 Dec 11;7:157-67
pubmed: 26715860
N Engl J Med. 2010 Feb 4;362(5):402-15
pubmed: 20089954
Lancet Neurol. 2014 Jun;13(6):545-56
pubmed: 24685276
Neurology. 2015 Apr 14;84(15):1582-91
pubmed: 25795646
Scientifica (Cairo). 2013;2013:249101
pubmed: 24278770
Lancet. 2016 Mar 12;387(10023):1075-1084
pubmed: 26827074
N Engl J Med. 2010 Feb 4;362(5):387-401
pubmed: 20089952
BMC Neurol. 2014 Nov 26;14:220
pubmed: 25424122
J Neurol. 2013 Aug;260(8):2023-32
pubmed: 23632946
J Neurol. 2014 Feb;261(2):267-76
pubmed: 24221641
Mult Scler. 2015 May;21(6):786-90
pubmed: 25257618
J Neurol Neurosurg Psychiatry. 2016 May;87(5):468-75
pubmed: 26111826
J Med Econ. 2014 Oct;17(10):696-707
pubmed: 25019581
PLoS One. 2014 Feb 06;9(2):e88472
pubmed: 24516663
Health Qual Life Outcomes. 2004 Feb 26;2:12
pubmed: 14987333
Am J Manag Care. 2013 Feb;19(2 Suppl):S15-20
pubmed: 23544716
Acta Clin Croat. 2013 Mar;52(1):107-11
pubmed: 23837280
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Mult Scler Relat Disord. 2014 Jul;3(4):494-504
pubmed: 25877062
Lancet Neurol. 2010 May;9(5):520-32
pubmed: 20398859
Biomed J. 2014 Mar-Apr;37(2):41-9
pubmed: 24732658
Mult Scler Relat Disord. 2014 Sep;3(5):607-19
pubmed: 26265273
JAMA Neurol. 2015 Apr;72(4):405-13
pubmed: 25665031